Recent Advances in Immunotherapy for Hepatocellular Carcinoma

• Published in: Cancers Vol. 12; no. 4; p. 775
• Main Authors: Nakano, Shigeharu, Eso, Yuji, Okada, Hirokazu, Takai, Atsushi, Takahashi, Ken, Seno, Hiroshi
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 25.03.2020; MDPI AG
• Subjects: combination therapy; ctla-4; hepatocellular carcinoma; immune checkpoint inhibitor; immunotherapy; pd-1; Review; combination therapy; immune checkpoint inhibitor; CTLA-4; PD-1; hepatocellular carcinoma; immunotherapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12040775

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since most patients are diagnosed at advanced stage and the current systemic treatment options using molecular-targeted drugs remain unsatisfactory. However, the recent success of cancer immunotherapies has revolutionized the landscape of cancer therapy. Since HCC is characterized by metachronous multicentric occurrence, immunotherapies that induce systemic and durable responses could be an appealing treatment option. Despite the suppressive milieu of the liver and tumor immunosurveillance escape mechanisms, clinical studies of checkpoint inhibitors in patients with advanced HCC have yielded promising results. Here, we provide an update on recent advances in HCC immunotherapies. First, we describe the unique tolerogenic properties of hepatic immunity and its interaction with HCC and then review the status of already or nearly available immune checkpoint blockade-based therapies as well as other immunotherapy strategies at the preclinical or clinical trial stage.